12 Jun 2008 15:50
12 June 2008
Akers Biosciences, Inc. ("ABI" or the "Company")
Placing update
Further to the announcement on 11 June 2008 that a consortium of private investors, acting through Saltburn Limited, a company incorporated in the Channel Islands, had exercised an option, granted by the Company on 4 June 2008, to invest £2.275m into ABI, by way of a subscription for 17,500,000 new common shares ("Shares"), the Company announces that admission of these Shares to trading on AIM is now expected to take place on 20 June 2008.
Admission of the 22,768,824 new common shares (as a result of the conversion by Brittany Capital) to trading on AIM, is expected to take place on 13 June 2008
Enquiries:
Thomas A. Nicolette
President and CEO
Tel. +1 856 848 8698
Ben Simons or Eleanor Williamson
M: Communications
Tel. +44 (0)20 7153 1540
Alasdair Younie
Arbuthnot Securities Limited
Tel. +44 (0)20 7012 2139